using realtime polymerase chain reaction (PCR) and Western blot analysis respectively. Our study provides a basis for the treatment of esophageal cancer at the molecular level.
Esophageal carcinoma cell line EC9706 was reserved in our lab. Bmi1 small interfering RNA (siRNA) (h) and an tibodies against Bmi1, p16, Bcl2, Bax, MMP2 and 茁 actin were purchased from Santa Cruz. One step realtime PCR kit (Quant) was purchased from Tiangen Biotech (Beijing). Cell Counting Kit8 (CCK8) was purchased from China Be yotime institute of Biotechnology. Protein lysis buffer was purchased from TaKaRa Biotechnology (Dalian). Boyden chambers were purchased from Qilin Medical Instrument Factory (Haimen, Jiangsu province). Primers for realtime PCR are shown in Table 1 . The primers were synthesized by Sangon Biotech (Shanghai). EC9706 cells were cultured in RPMI1640 medium containing 100 units/mL penicillin, 100 滋 g/mL streptomycin, 50 滋 g/mL azithromycin and 10% FBS at 37益 in a humid incubator with 5% CO 2 . Experimental cells were at logarithmic phase. When cells reached more than 90% confluence, EC9706 cells were transfected with either scramble siRNA or Bmi1 siRNA using Lipofectamine TM 2000 according to the manufacturer爷s instruction . Three groups were defined as follows : the untreated group, the scramble siRNA treated group, and the Bmi1 siRNA treated group.
CCK8 is a sensitive, non radioactive colorimetric analysis, which detects the number of living cells as a means to measure cell proliferation. CCK8 solution can be directly added to cell medium. Detailed procedures to measure cell growth rates were as follows: cells were harvested 0 h, 24 h, 48 h, 72 h, and 96 h after transfection and then incubated with additional equal amount of fresh medium containing 10% of CCK8 at 37益 for 14 h. The absorbance at 450 nm was measured using a microplate reader.
A total of 1 伊 10 6 untreated and transfected EC9706 cells were harvested 24 h after transfection, rinsed with PBS buffer, and fixed at 4益 for 30 min using 70% cold ethanol, respectively. After fixation, the cells were washed for three times with cold PBS, resuspended in PBS containing 40 滋 g propidium iodide and 100 滋 g RNase A and then incubated at 37益 for 30 min. Finally, DNA contents were analyzed by flow cytometry (FCM). Apoptosis was determined as described by Lu . [5] . The three abovedefined groups of cells were harvested 24 h after transfection, washed with cold PBS , and resuspended at 1 伊 10 6 cells/mL. In each group, 100 滋 L of EC9706 cells were incubated with 5 滋 L Annexin VFITC (BD Biosciences Inc.) and 5 滋 L PI for 15 min in dark. Subsequently, 1 伊 10 4 cells were measured by FCM and results were analyzed using Cell Quest software.
Cell migration was measured using Boyden chamber assay. Briefly, three groups of cells (about 1 伊 10 5 cells in each group) were suspended in 800 滋 L of cell medium containing 0.2% calf serum, inoculated in the upper Boyden chamber, and cultured for 6 h. Cells which have migrated to the lower membrane were fixed with methanol and stained by HE staining. The invading cells in 30 microscopic views were counted in the lower chamber under 200 伊 magnifications.
Total RNAs were extracted using Trizol reagent. Realtime PCR was then performed using Quant Onestep realtime PCR kit according to the manufacturer爷s protocol. Briefly, after the reverse transcription reaction at 50益 for 30 min, cDNAs were initially denatured at 94益 for 2 min, and followed by 35 cycles of repeated procedure as follows: denatured at 94益 for 30 s, annealed for 30 s (the respective annealing temperature for each gene is listed in Table 1 ), and extent at 65益 for 30 s. PCR was carried out using Applied Biosystems 7300 realtime PCR system. Independent experiments were repeated 3 times for each sample and the relative expression levels of genes were analyzed using 2 △△Ct method [6] . EC9706 cells were collected in lysis buffer 24 h after transfection and centrifuged down at 16 000 伊 for 5 min. The protein concentration was determined using Bradford method. A total of 80 滋 g proteins were boiled for 5 min, separated in 10% SDSPAGE, and transferred to a nitrocellulose membrane. The membrane was blocked in TBST containing 5% milk at room temperature for 2 h, and incubated overnight with the primary antibodies in the blocking buffer at 4益. Subsequently, the membrane was washed with TBST for 3 times and incubated with appropriate secondary antibodies for another 1 h. After washing with TBST for 3 times, the films were developed. The relative protein expression level was quantified using ImagePro Plus 5.0 software. SPSS13.0 statistical software was used for statistical analyses. Statistical data were represented as mean 依 standard deviation. Student test was used to compare two samples and the singlefactor analysis of variance (Oneway ANOVA) was used to compare multiple samples. A value of < 0.05 was considered as significantly different.
Cells in three groups were harvested at 24 h, 48 h, 72 h, and 96 h after Bmi1 siRNA treatment. CCK8 kit results showed the proliferation rate of EC9706 cells was not significantly different between the untreated and scramble siRNA treated groups at each time point ( = 0.700, 0.123, 0.534, 0.459, respectively). However, the proliferation rate of EC9706 cells was significantly lower in the Bmi1 siRNA treated group than in the untreated and scramble siRNA treated groups (both < 0.001) (Figure 1 ). These results suggest that downregulation of Bmi1 significantly inhibits the proliferation of EC9706 cells. Three groups of cells were collected for cell cycle analysis 24 h after treatment. The results showed that 47.36% of the untreated cells and 48.47% of the scramble siRNA treated cells were at G 0 /G 1 phase, which was significantly lower than that of the Bmi1 siRNA treated cells (71.93%) ( < 0.001). By contrast, the number of cells at S phase was lowest in the Bmi1 siRNA treated group ( Figure  2 ). These results suggest that Bmi1 siRNA treatment retains EC9706 cells at G 0 /G 1 phase and blocks DNA synthesis.
Three groups of cells were harvested 24 h after treatment and apoptosis was analyzed using flow cytometry. Early stage of apoptosis in the Bmi1 siRNA treated group (17.32% ) was significantly higher than that in the untreated (2.61% ) and scramble siRNA treated (2.73% ) groups (both < 0.001). There was no statistical difference between the untreated and scramble siRNA treated groups ( = 0.852). In addition, the number of living cells in the untreated or scramble siRNA treated groups were significantly larger Cells were inoculated in the upper chamber 24 h after treatment. Compared with the untreated (152.29 依 5.92) and scramble siRNA treated (147.63 依 6.13) groups, the number of invading EC9706 cells decreased significantly after Bmi1 siRNA treatment (70.38 依 5.17) ( < 0.001). In addition, no difference between the untreated and scramble siRNA treated groups was observed ( = 0.360). These results suggest Bmi1 siRNA treatment inhibits the migration of EC9706 cells.
Total RNAs were extracted 24 h after that cells were treated with scramble siRNA or Bmi1 siRNA. Realtime PCR were performed using Quant onestep realtime PCR kit. Specific bands were obtained for cell proliferation and cell cyclerelated gene p16, apoptosis related genes Bcl2 and Bax, as well as invasion and metastasis related factor MMP2 (Figure 4) . The mRNA expression levels of these genes were similar in the untreated and scramble siRNA treated EC9706 cells. In the Bmi1 siRNA treated EC9706 cells, the mRNA expression of Bmi1, Bcl2 and MMP2 was significantly downregulated (all < 0.001), whereas that of p16 and proapoptotic gene Bax was upregulated (both < 0.001) ( Figure 5 ).
Total proteins were extracted 24 h after treatment and were subjected to Western blot analysis. There was no difference in the expression levels of Bmi1, p16, Bcl2, Bax and MMP2 between the untreated and scramble siRNA, Bmi1 was first characterized in cancer cells by the Netherlands Cancer Institute in 1991, which is involved in the proliferation of cancer stem cells and tumorigenesis [7] . Increasing evidence showed that Bmi1 not only plays a critical role in tumorigenesis and tumor growth, but is also a valuable factor in clinical prognosis [8, 9] . Thus, Bmi1 is a new potential marker for cancer diagnostic and therapeutic target. Studies have shown that the expression level of Bmi1 increases in a variety of malignant tumors, and is related to prognosis of many cancers such as gastric cancer [2] , ovarian cancer [3] , chronic myeloid leukemia [10] , head and neck cancer [8] , breast [9] , bladder cancer [11] , and so on. However, the role of Bmi1 in esophageal cancer is unknown yet. In this study, we transfected Bmi1 siRNA into EC9706 cells to study the effect of Bmi1 downregulation on cell proliferation, cell cycle, cell apoptosis and invasiveness, and explored its mechanisms. The present study aimed to provide evidence of this new therapeutic target for treating esophageal cancer. Recent studies showed that Bmi1 plays an important role in the regulation of tumor cell proliferation and cell cycle. Knockout of Bmi1 gene in human hepatocarcinoma HepG2 cells inhibits cell proliferation [12] . Jocobs . [13] studied the function of Bmi1 in cell proliferation using mouse embryonic fibroblasts (MEFs). They found that cells are difficult to enter S phase when Bmi1 is repressed. The proliferation rate and cell density of wild type MEFs are significantly higher than those of the Bmi1 knockout ones. In addition, knockout of Bmi1 gene in gastric cancer cell AGS leads to inhibition of cell growth [2] . In this study, we found that downregulation of Bmi1 using Bmi1 siRNA inhibits the proliferation of esophageal carcinoma EC9706 cells. A majority of cells are arrested at G 0 /G 1 phase and DNA synthesis is inhibited, which eventually leads to the inhibition of proliferation. P16 was found as a new anticancer gene by Kamb . in Cold Spring Harbor Laboratory in 1994. P16 is an essential cell cycle related gene and participates in cell cycle regulation. P16 inhibits cell cycledependent kinase 4 ( CDK4) directly, and thereby inhibits cell cycle progression and cancer cell growth. To identify whether p16 is involved in Bmi1 regulation of cancer cell growth, we detected the expression levels of p16. We found that the expression of p16 increases significantly at both mRNA and protein levels. These data suggest that the inhibition of EC9706 cell proliferation and cell cycle progression by Bmi1 downregulation is mediated by the upregulation of p16.
Tumorigenesis is the result of an imbalance between cell proliferation and cell apoptosis. It is an effective way to treat cancer by inducing cancer cell apoptosis. Some studies have shown that the effect of Bmi1 downregulation on cell cycle and cell apoptosis is celltype specific. The proportion of Bmi1 / leukemia cells at G 0 /G 1 phase increases than that of wild鄄 type cells. In the meanwhile, the proportion of cells at S phase decreased and cell apoptosis increases [14] .
However, neither cell cycle nor apoptosis is affected in human neuroblastoma BE (2)C cells by the downregulation of Bmi1 [15] . Our results showed that the early apoptosis rate of EC9706 cells treated with Bmi1 siRNA is significantly higher than that of the untreated and scramble siRNA treated cells. Because antiapoptotic gene Bcl2 and proapoptotic gene Bax are two important regulators of cell apoptosis, we further detected the expression levels of these two genes at mRNA and protein levels using realtime PCR and Western blot. We found that the expression level of Bcl2 is significantly lower in the Bmi1 siRNA treated group than in the untreated and scramble siRNA treated groups, while the expression level of Bax is higher. Therefore, inhibition of Bmi1 expression induces cell apoptosis, which may be mediated by the downregulation of Bcl2 and upregulation of Bax. Further studies are needed to delineate the additional mechanisms.
In addition to participating in malignant tumorigenesis and tumor progression, Bmi1 is implicated in tumor invasion, metastasis, and prognosis. By analyzing transgenic mice and 1153 patients who were diagnosed with ten different types of cancer using comparative genomics approach, Glinsky . [16] suggested 11 genes exists in the conservative Bmi1 signaling pathway. Further studies showed that the expression patterns of these 11 genes may predict tumor metastasis, recurrence, and death in various types of cancer patients. In addition, the activation of Bmi1 associated PcG pathway plays an important role in the progression of metastatic prostate cancer [17] . Feng . [18] found that Bmi1 overexpression is corelated with breast cancer metastasis and TNM stage. In this study, we detected migration of EC9706 cells after Bmi1 siRNA treatment using Boyden chamber assay and measured the expression of a closely related factor, MMP2, using realtime PCR and Western blot. Our results showed that Bmi1 siRNA decreases significantly EC9706 cell migration. In addition, the expression of MMP2 at both mRNA and protein levels decreases significantly. These results imply a direct relationship between lower EC9706 cell migration and lower expression of MMP2, however, specific mechanism remains to be elucidated. In summary, this study focuses on the role of Bmi1 in esophageal cancer, and reveals that the inhibition of Bmi1 expression inhibits cell growth, arrests cell cycle, induces cell apoptosis, and decreases cell invasion, which are closely related to the changes in the expression of p16, Bcl2, Bax, and MMP2. Further studies illuminating the molecular mechanisms of cancer inhibition by Bmi1 will shed light on using Bmi1 as a molecular target to treat esophageal cancer.
